Domperidone and levodopa in Parkinson's disease

Area of Science:

• Pharmacology
• Neurology
• Clinical Medicine

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms resulting from dopamine deficiency.
• Levodopa remains the most effective treatment for PD, but its absorption and efficacy can be variable.
• Domperidone is a peripheral dopamine antagonist used to manage nausea and vomiting, often associated with levodopa treatment.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic interaction between levodopa and domperidone in patients with idiopathic Parkinson's disease.
• To determine the effect of domperidone pre-treatment on levodopa absorption and its impact on clinical response.

Main Methods:

• A study involving 15 patients with idiopathic Parkinson's disease.
• Patients received levodopa (500 mg) orally, both alone and after pre-treatment with varying doses of domperidone (10, 20, 40 mg) via oral, intravenous, or intramuscular routes.
• Plasma levodopa concentrations and Parkinsonian disability scores were monitored.

Main Results:

• Domperidone pre-treatment resulted in a mean 12% increase in peak plasma levodopa concentration.
• The time to peak levodopa concentration was reduced by a mean of 10 minutes with domperidone.
• Parkinsonian disability scores improved, with peak clinical response occurring 16 minutes earlier compared to levodopa alone.

Conclusions:

• Domperidone administration slightly enhances the immediate bioavailability of levodopa.
• Domperidone pre-treatment improves the anti-Parkinsonian response to levodopa, leading to a faster onset of clinical benefits.